← Back to Search

Behavioral Intervention

Resilience Coaching for Adolescent Chronic Pain

N/A
Recruiting
Led By Sabrina Gmuca, MD MSCE
Research Sponsored by Children's Hospital of Philadelphia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured at 3 months post-randomization.
Awards & highlights
No Placebo-Only Group

Summary

This trial will research how resilience coaching could help teens with chronic pain. It'll compare those who receive resilience coaching to those who receive usual care. Results will show if it helps with functional disability, psychological distress, and pain intensity.

Who is the study for?
Adolescents aged 12-17 with chronic musculoskeletal pain, which includes bone, joint, muscle or related soft tissue pain lasting more than 3 months. They must have a caregiver to participate alongside them and both should primarily speak English. Those already receiving cognitive behavioral therapy or diagnosed with complex regional pain syndrome are excluded.
What is being tested?
The trial is testing the effectiveness of resilience coaching (PRISM) for teens with chronic musculoskeletal pain compared to usual care. It aims to see if PRISM can better improve how these adolescents cope with disability, psychological distress, and pain intensity.
What are the potential side effects?
Since this intervention involves coaching rather than medication, traditional side effects like those seen in drug trials may not apply. However, participants might experience emotional discomfort when discussing personal issues during sessions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured at 3 months post-randomization.
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at 3 months post-randomization. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Functional Disability
Secondary study objectives
Pain intensity
Psychological distress

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Resilience Coaching plus Usual CareExperimental Treatment1 Intervention
Promoting Resilience in Stress Management (PRISM) is a 1:1, remotely delivered, resilience coaching program for adolescents with chronic illness, consisting of skill-building sessions in stress management, goal setting, cognitive re-framing, and benefit-finding. Sessions are held every 1-2 weeks for a total of 4 required and one optional session and each session lasts about 30-45 minutes.
Group II: Usual CareActive Control1 Intervention
Usual care consists of an individualized treatment combining physical therapy, occupational therapy and psychological counseling. This is determined by the treating provider.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Promoting Resilience in Stress Management
2016
N/A
~110

Find a Location

Who is running the clinical trial?

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH
502 Previous Clinical Trials
1,089,778 Total Patients Enrolled
Children's Hospital of PhiladelphiaLead Sponsor
731 Previous Clinical Trials
8,472,079 Total Patients Enrolled
Sabrina Gmuca, MD MSCEPrincipal InvestigatorChildren's Hospital of Philadelphia

Media Library

Promoting Resilience in Stress Management (PRISM) (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05834725 — N/A
Complex Regional Pain Syndrome Research Study Groups: Usual Care, Resilience Coaching plus Usual Care
Complex Regional Pain Syndrome Clinical Trial 2023: Promoting Resilience in Stress Management (PRISM) Highlights & Side Effects. Trial Name: NCT05834725 — N/A
Promoting Resilience in Stress Management (PRISM) (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05834725 — N/A
~42 spots leftby May 2025